Results 161 to 170 of about 5,796 (217)

Economic evaluations of RSV preventive strategies: a systematic review of cost-effectiveness and modeling approaches. [PDF]

Front Public Health
Zhu B, Lu Y, Zhou Y, Li W, Wu Y, Bao Y, Lu Y.   +6 more
europepmc   +1 more source

Human iPS cell-derived respiratory organoids as a model for respiratory syncytial virus infection. [PDF]

Life Sci Alliance
Hashimoto R, Watanabe Y, Keshta A, Sugiyama M, Kitai Y, Hirabayashi A, Yasuhara N, Morimoto S, Sakamoto A, Matsumura Y, Nishimura H, Noda T, Yamamoto T, Nagao M, Takeda M, Takayama K.   +15 more
europepmc   +1 more source

Increased Respiratory Syncytial Virus-Associated Hospitalizations and Ambulatory Visits in Very Preterm Infants in the First Year of Life following Discontinuation of Access to Palivizumab. [PDF]

Am J Perinatol
Evong Y, Luo J, Ye L, Fahey J, Breeze JL, Attenborough R, Wong K, Langley JM.   +7 more
europepmc   +1 more source

Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy. [PDF]

Glob Reg Health Technol Assess
Marcellusi A, Bini C, Muzii B, Soudani S, Kieffer A, Beuvelet M, Bozzola E, Midulla F, Baraldi E, Bonanni P, Boccalini S, Orfeo L.   +11 more
europepmc   +1 more source

Dynamics of Respiratory Syncytial Virus Illness and Serology During Pregnancy and Infancy in the United States and South Africa. [PDF]

Open Forum Infect Dis
Madhi SA, Simões EAF, Klein NP, Zareba A, Dormitzer PR, Scott DA, Gurtman A, Gruber WC, Jansen KU, Cooper D, Cai B, Schmoele-Thoma B, Swanson KA.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Palivizumab

Drugs, 1999
The humanised monoclonal antibody palivizumab has been developed for prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants at high risk; RSV is the most common cause of lower respiratory tract infections in infants.
L J, Scott, H M, Lamb
  +5 more sources

Comments on Palivizumab (Synagis)

Pediatrics, 1999
Caregivers and third-party payors need additional information from the Impact study1investigators to determine the appropriate use of palivizumab (Synagis) in select premature infants with increased risk of respiratory syncytial virus (RSV)-associated hospitalization.
F W, Moler, R W, Brown, R G, Faix, J R, Gilsdorf   +3 more
openaire   +2 more sources

Palivizumab: A debate about funding

Journal of Paediatrics and Child Health, 2010
AbstractA clinician and the chair of the hospital drug committee debate the merits of the use of palivizumab as prophylaxis against respiratory syncytial virus infection for a preterm baby with oxygen‐dependent, chronic lung disease and discuss the issue of public funding of palivizumab.
Fitzgerald, Dominic, Isaacs, David, Tobin, Bernadette   +2 more
openaire   +3 more sources